Single Source: Outcomes of Electronic Medical Records and Genomics (eMERGE) Genomic Risk Assessment and Management Network - Coordinating Center (U01 Clinical Trial Required)

The summary for the Single Source: Outcomes of Electronic Medical Records and Genomics (eMERGE) Genomic Risk Assessment and Management Network - Coordinating Center (U01 Clinical Trial Required) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Single Source: Outcomes of Electronic Medical Records and Genomics (eMERGE) Genomic Risk Assessment and Management Network - Coordinating Center (U01 Clinical Trial Required): This is a Notice of Funding Opportunity (NOFO) for a Single Source that invites a recipient organization funded under the Electronic Medical Records and Genomics (eMERGE): Genomic Risk Assessment and Management Network Coordinating Center (RFA-HG-19-015) to participate in the Outcomes of Electronic Medical Records and Genomics (eMERGE) Genomic Risk Assessment and Management Network. Please see Section III. Eligibility for additional information. In accordance with NIH standard peer-review processes, the application will be peer-reviewed, and only meritorious applications will be considered.The NHGRI is announcing its intent to issue a single source cooperative agreement award to Vanderbilt University Medical Center to continue coordination of the eMERGE Risk Assessment Network. The eMERGE Network will extend through April 2030 follow-up and collection of outcome data on the roughly 25,000 patients receiving genomically informed risk assessment (GIRA) and management recommendations.